LPL Financial LLC Acquires 1,268 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

LPL Financial LLC lifted its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 15.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,400 shares of the specialty pharmaceutical company’s stock after buying an additional 1,268 shares during the period. LPL Financial LLC’s holdings in Jazz Pharmaceuticals were worth $1,165,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in JAZZ. US Bancorp DE increased its holdings in shares of Jazz Pharmaceuticals by 13.3% in the 1st quarter. US Bancorp DE now owns 2,736 shares of the specialty pharmaceutical company’s stock worth $427,000 after buying an additional 322 shares during the last quarter. Private Advisor Group LLC bought a new position in Jazz Pharmaceuticals during the 1st quarter valued at about $547,000. Aviva PLC grew its holdings in Jazz Pharmaceuticals by 87.1% during the 1st quarter. Aviva PLC now owns 40,005 shares of the specialty pharmaceutical company’s stock valued at $6,228,000 after purchasing an additional 18,628 shares during the last quarter. Allianz Asset Management GmbH grew its holdings in Jazz Pharmaceuticals by 118.2% during the 1st quarter. Allianz Asset Management GmbH now owns 12,130 shares of the specialty pharmaceutical company’s stock valued at $1,888,000 after purchasing an additional 6,571 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in Jazz Pharmaceuticals by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 5,602,650 shares of the specialty pharmaceutical company’s stock valued at $872,164,000 after purchasing an additional 57,949 shares during the last quarter. 88.15% of the stock is currently owned by institutional investors.

Insider Transactions at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 1,500 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $144.25, for a total value of $216,375.00. Following the completion of the sale, the executive vice president now owns 29,186 shares of the company’s stock, valued at approximately $4,210,080.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.40% of the company’s stock.

Wall Street Analyst Weigh In

JAZZ has been the topic of several analyst reports. Raymond James initiated coverage on shares of Jazz Pharmaceuticals in a report on Thursday, September 28th. They set a “market perform” rating on the stock. Needham & Company LLC cut their price target on shares of Jazz Pharmaceuticals from $226.00 to $225.00 and set a “buy” rating on the stock in a report on Thursday, November 9th. HC Wainwright reiterated a “buy” rating and set a $204.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, August 11th. Bank of America boosted their price objective on shares of Jazz Pharmaceuticals from $204.00 to $217.00 and gave the company a “buy” rating in a research report on Thursday, August 10th. Finally, Royal Bank of Canada lowered their price objective on shares of Jazz Pharmaceuticals from $200.00 to $191.00 and set an “outperform” rating for the company in a research report on Thursday, November 9th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $204.83.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $121.79 on Friday. The company has a 50 day moving average price of $129.82 and a 200-day moving average price of $131.13. Jazz Pharmaceuticals plc has a fifty-two week low of $115.97 and a fifty-two week high of $160.96. The stock has a market capitalization of $7.67 billion, a PE ratio of 138.40, a PEG ratio of 0.97 and a beta of 0.73. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.67 and a current ratio of 2.06.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors.